---
figid: PMC9106028__cancers-14-02049-g001
pmcid: PMC9106028
image_filename: cancers-14-02049-g001.jpg
figure_link: /pmc/articles/PMC9106028/figure/cancers-14-02049-f001/
number: Figure 1
figure_title: ''
caption: 'Mechanism of action of experimental and Food and Drug Administration-approved
  drugs. In this figure, only the major molecules in each pathway are depicted. Created
  with BioRender.com. Abbreviations: FGF—fibroblast growth factor; FGFR—FGF receptor;
  PDGF—platelet-derived growth factor receptor; PDGFR—PDGF receptor; VEGF—vascular
  endothelial growth factor; VEGFR—VEGF receptor; MET—hepatocyte growth factor receptor;
  RTK—receptor tyrosine kinase; PI3K—phosphoinositide 3-kinase; AKT—protein kinase
  B; mTOR—mechanistic target of rapamycin complex; APC—antigen-presenting cell; PD-1—programmed
  cell death protein; PD-L1—PD-1 ligand 1; PD-L2—PD-1 ligand 2; HIF—hypoxia-inducible
  factor; HRE—hypoxia response element; pVHL—von Hippel–Lindau protein.'
article_title: 'Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective
  on the Current Algorithm and Future Directions.'
citation: Ameish Govindarajan, et al. Cancers (Basel). 2022 May;14(9):2049.
year: '2022'

doi: 10.3390/cancers14092049
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI

keywords:
- renal cell carcinoma
- targeted therapy
- immunotherapy

---
